drugset / Trial / NCT04523844

Brinzolamide-brimonidine Fixed Combination for Preventing IOP Elevation After Intravitreal Anti-VEGF Injections

NCT04523844

Completed 47 enrolled General Hospital of Athens Elpis
RandomizedParallel-groupSingle-blindTreatment

Summary

This study aims to evaluate the effect of topical prophylaxis with brinzolamide-brimonidine fixed combination on short-term intraocular pressure (IOP) elevation after intravitreal injections of anti-vascular endothelial growth factors (anti-VEGF). Patients scheduled for treatment with intravitreal injections of anti-VEGF will be randomly divided into two groups. In control group no prophylactic medication will be used, whereas in case group one drop of brinzolamide-brimonidine fixed combination will be instilled two hours before the injection. IOP will be measured before the injection, 1 minute after the injection, 10 minutes and 30 minutes post-injection in all eyes. In case group, the pre-injection IOP will be measured prior to the administration of the fixed combination of brinzolamide-brimonidine. The iCare (IC200) tonometer will be used for IOP measurements at all time points.

Timeline

Start
2020-05-11
Primary completion
2020-07-30
Completion
2020-07-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Brimonidine Small molecule 0.2 % Topical
Comparator Brinzolamide Small molecule 1 % Topical

Indications